Home > Back to Publisher > Report Information

Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine

Datamonitor
October 21, 2009
51 Pages - SKU: DFMN2482221

Abstract Table of Contents Related Reports

Introduction

CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018.

Scope

Examination of the CRC pipeline with in-depth clinical and commercial profiles of Phase III candidates
Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2018
Segmentation and analysis of the current CRC pipeline by developmental phase, drug class and company
Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs

Highlights

The CRC pipeline consists of 77 drugs, of which 60% are molecular targeted therapies (MTTs), 22% are immunotherapies, and 17% are cytotoxic therapies. MTTs constitute the bulk of the CRC pipeline. This is in line with R&D in other tumor types, where there is a shift away from standard cytotoxic therapies towards MTTs and personalized medicine.

The late-phase CRC pipeline consists only of MTTs. Except for one agent; all the others are being investigated in previously-treated patients. Drug developers appear to be pursuing approval for treatment in the second-line setting where barriers to market entry are lower and the high level of unmet need may facilitate a drug's uptake and approval.

Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) is forecast to achieve the highest level of sales among the late-phase pipeline candidates in the CRC market, generating £604m by 2018 in the seven major pharmaceutical markets.

Reasons to Purchase

Identify key drugs and companies within the CRC pipeline based on sales forecasts to 2018 and Datamonitor drug assessment.
Characterize unmet need and poorly served patient subsets within the CRC market and assess the potential for pipeline products to fulfil them.
Segmentation and analysis of the current CRC pipeline by developmental phase, drug class, company and indication.

Please note: this is delivered as a Zip file.

Overview: Catalyst; Summary
ABOUT DATAMONITOR HEALTHCARE: About the Oncology pharmaceutical analysis team; Executive Summary; Strategic scoping and focus; Datamonitor insight into the colorectal cancer market; Datamonitor pipeline assessment summary; Related reports; Upcoming related reports; Table of Contents; 1. Pipeline Overview and dynamics; 2. Colorectal cancer - Market Potential; 3. R&D Approach; 4. Pipeline Analysis & Forecasts: Molecular Targeted Therapies; 5. Innovative Early-Stage Approaches
APPENDIX: Methodology; Epidemiology forecasts; Product forecasts; Datamonitor drug assessment scorecard; Contributing experts; About Datamonitor; About Datamonitor Healthcare; About the Oncology analysis team; Datamonitor consulting; Disclaimer
List of Tables: Table 1: Sales forecasts for late-phase colorectal cancer (CRC) pipeline products in the seven major markets ($m), 2009-2018; Table 2: Drugs in late-phase development for colorectal cancer (CRC), 2009; Table 3: Sales forecasts for late-stage colorectal cancer (CRC) pipeline products in the seven major markets ($m), 2009-2018; Table 4: Amgen's marketed and pipeline oncology portfolio, 2009; Table 5: AstraZeneca's marketed and pipeline oncology portfolio, 2009; Table 6: Roche's marketed and pipeline oncology portfolio, 2009; Table 7: Forecast incidence of colorectal cancer (CRC) in the seven major pharmaceutical markets, 2009-2018; Table 8: Molecular targeted therapies (MTTs) approved for use in metastatic colorectal cancer (CRC), 2009; Table 9: Eloxatin (oxaliplatin) - drug profile, 2009; Table 10: Ability of Eloxatin to meet unmet needs in the first-line treatment of metastatic colorectal cancer (CRC), 2009; Table 11: Ability of Eloxatin to meet unmet needs in the second-line treatment of metastatic colorectal cancer (CRC), 2009; Table 12: Drugs in late-phase development for colorectal cancer (CRC) , 2009; Table 15: Sales forecasts for late-phase colorectal cancer (CRC) pipeline products in the seven major markets ($m), 2009-2018; Table 16: Aflibercept - drug profile, 2009; Table 17: Aflibercept: key historical events; Table 18: Clinical development of aflibercept in colorectal cancer (CRC), 2009; Table 19: Ability of aflibercept to meet unmet needs in colorectal cancer (CRC), 2009; Table 20: Sales forecast for aflibercept in colorectal cancer (CRC) across the seven major markets ($m), 2009-2018; Table 21: Brivanib - drug profile, 2009; Table 22: Brivanib: key historical events; Table 23: Clinical development of brivanib in colorectal cancer (CRC), 2009; Table 24: Phase I results investigating a second-line or higher combination of Erbitux and brivanib in advanced gastrointestinal malignancies; Table 25: Ability of brivanib to meet unmet needs in colorectal cancer (CRC), 2009; Table 26: Sales forecast for brivanib in colorectal cancer (CRC) across the seven major markets($m), 2009-2018; Table 27: Recentin (cediranib) - drug profile, 2009; Table 28: Recentin: key historical events; Table 29: Clinical development of Recentin in colorectal cancer (CRC), 2009; Table 30: Ability of Recentin to meet unmet needs in colorectal cancer (CRC), 2009; Table 31: Sales forecast for Recentin in colorectal cancer (CRC) across the seven major markets ($m), 2009-2018; Table 32: MK-0646 - drug profile, 2009; Table 33: MK-0646: key historical events; Table 34: Clinical development of MK-0646 in colorectal cancer (CRC), 2009; Table 35: Ability of MK-0646 to meet unmet needs in colorectal cancer (CRC), 2009; Table 36: Sales forecast for MK-0646 in colorectal cancer (CRC) across the seven major markets, 2009-2018 ($m); Table 37: Top 10 early-stage colorectal cancer (CRC) drug targets, 2009; Table 38: Datamonitor drug assessment parameters
List of Figures: Figure 1: Datamonitor drug assessment summary for molecular targeted therapies (MTTs) in development for colorectal cancer (CRC), 2009; Figure 2: Colorectal cancer (CRC) pipeline split by development phase and drug class, 2009; Figure 3: Datamonitor drug assessment summary for molecular targeted therapies (MTTs) in development for colorectal cancer (CRC), 2009; Figure 4: Incidence and mortality from colorectal cancer (CRC) in the seven major pharmaceutical markets, 2009 and 2018; Figure 5: Incidence of colorectal cancer (CRC) in the rest of the world, 2009 and 2019; Figure 6: Datamonitor drug assessment summary for molecular targeted therapies in development for colorectal cancer (CRC), 2009; Table 13: Forecast assumptions for molecular targeted therapy colorectal cancer (CRC) pipeline products across the seven major markets, 2009; Table 14: Forecast assumptions for molecular targeted therapy colorectal cancer (CRC) pipeline products across the seven major markets, 2009; Figure 7: SWOT analysis for aflibercept, 2009; Figure 8: Phase II data on the second-line treatment of aflibercept in recurrent metastatic colorectal cancer (CRC) patients following failure of standard therapy; Figure 9: Datamonitor drug assessment summary for aflibercept in colorectal cancer (CRC), 2009; Figure 10: Brivanib SWOT analysis, 2009; Figure 11: Retrospective analysis evaluating correlation between KRAS status and efficacy from a Phase I/II study of brivanib in combination with Erbitux in patients with advanced or metastatic colorectal cancer (CRC); Figure 12: Datamonitor drug assessment summary for brivanib in colorectal cancer (CRC), 2009; Figure 13: SWOT analysis for Recentin, 2009; Figure 14: Phase II results for second-line FOLFOX + Recentin versus FOLFOX + Avastin in metastatic colorectal cancer (CRC) (HORIZON I); Figure 15: Datamonitor drug assessment summary for Recentin in colorectal cancer (CRC), 2009; Figure 16: SWOT analysis for MK-0646, 2009; Figure 17: Phase II study of MK-0646 in second-line or higher metastatic colorectal cancer (CRC) patients with wild-type KRAS; Figure 18: Datamonitor drug assessment summary for MK-0646 in colorectal cancer (CRC), 2009; Figure 19: Early-stage colorectal cancer pipeline (CRC) split by drug class, 2009; Figure 20: Datamonitor drug assessment summary for molecular targeted therapies in development for colorectal cancer (CRC), 2009

Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine

Share this report

Other tasks

Research Assistance

Related Markets

Oncology/Hematology Reports

Free Alert Me service